Assessment of Differential Pharmacodynamic Effects Using Optical Coherence Tomography in Neovascular Age-Related Macular Degeneration

PURPOSE. To use novel OCT parameters in assessing the differential pharmacodynamic effects of bevacizumab (Avastin; Genentech, South San Francisco, CA), pegaptanib (Macugen; OSI Pharmaceuticals, New York, NY), and verteporfin photodynamic therapy (PDT; Novartis, Basel, Switzerland) in a recently com...

Description complète

Enregistré dans:
Détails bibliographiques
Auteurs principaux: Keane, Pearse A., Heussen, Florian M., Ouyang, Yanling, Mokwa, Nils, Walsh, Alexander C., Tufail, Adnan, Sadda, Srinivas R., Patel, Praveen J.
Format: Artigo
Langue:Inglês
Publié: Association for Research in Vision and Ophthalmology, Inc. 2012
Sujets:
Articles
Accès en ligne:https://ncbi.nlm.nih.gov/pmc/articles/PMC3339900/
https://ncbi.nlm.nih.gov/pubmed/22281826
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1167/iovs.11-8130
Tags: Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!

Documents similaires